Design Therapeutics, Inc. (NASDAQ:DSGN) Expected to Announce Earnings of -$0.24 Per Share

Brokerages expect that Design Therapeutics, Inc. (NASDAQ:DSGNGet Rating) will report ($0.24) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Design Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.23). Design Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which would indicate a negative year-over-year growth rate of 71.4%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Design Therapeutics will report full-year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.12) to ($0.96). For the next fiscal year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.68) to ($1.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Design Therapeutics.

Design Therapeutics (NASDAQ:DSGNGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02).

A number of equities research analysts have issued reports on DSGN shares. Royal Bank of Canada started coverage on Design Therapeutics in a research report on Monday, May 2nd. They set an “outperform” rating and a $30.00 price objective on the stock. The Goldman Sachs Group started coverage on Design Therapeutics in a research report on Wednesday, January 19th. They set a “sell” rating and a $10.00 price objective on the stock.

In other Design Therapeutics news, Director Arsani William acquired 25,000 shares of the stock in a transaction dated Monday, March 21st. The stock was purchased at an average price of $18.99 per share, with a total value of $474,750.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stella Xu sold 565,425 shares of the firm’s stock in a transaction on Friday, March 18th. The stock was sold at an average price of $19.07, for a total value of $10,782,654.75. The disclosure for this sale can be found here.

Institutional investors have recently bought and sold shares of the company. Citigroup Inc. lifted its position in Design Therapeutics by 4.7% during the 3rd quarter. Citigroup Inc. now owns 24,808 shares of the company’s stock worth $364,000 after acquiring an additional 1,118 shares during the period. EcoR1 Capital LLC lifted its position in Design Therapeutics by 47.9% during the 3rd quarter. EcoR1 Capital LLC now owns 1,863,098 shares of the company’s stock worth $27,369,000 after acquiring an additional 603,079 shares during the period. Geode Capital Management LLC lifted its position in Design Therapeutics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 258,032 shares of the company’s stock worth $3,790,000 after acquiring an additional 5,272 shares during the period. TD Asset Management Inc. lifted its position in Design Therapeutics by 208.2% during the 3rd quarter. TD Asset Management Inc. now owns 65,718 shares of the company’s stock worth $965,000 after acquiring an additional 44,396 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Design Therapeutics by 4.3% during the 3rd quarter. Principal Financial Group Inc. now owns 220,510 shares of the company’s stock worth $3,239,000 after acquiring an additional 9,008 shares during the period. 65.01% of the stock is owned by hedge funds and other institutional investors.

Shares of Design Therapeutics stock opened at $11.07 on Tuesday. The stock has a 50 day moving average of $15.46 and a 200 day moving average of $16.07. Design Therapeutics has a 12 month low of $10.37 and a 12 month high of $29.16. The firm has a market cap of $616.60 million, a PE ratio of -12.87 and a beta of 2.09.

About Design Therapeutics (Get Rating)

Design Therapeutics, Inc a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.

Featured Stories

Get a free copy of the Zacks research report on Design Therapeutics (DSGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.